LCG
HZNP

Lisanti Capital Growth’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Lisanti Capital Growth’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-49,397
Closed -$3.94M – 143
2022
Q2 		$3.94M Sell
49,397
-38,115
-44% -$3.61M 0.54% 75
2022
Q1 		$9.21M Buy
87,512
+59,827
+216% +$5.83M 1.03% 35
2021
Q4 		$2.98M Sell
27,685
-960
-3% -$105K 0.43% 84
2021
Q3 		$3.14M Hold
28,645
– – 0.46% 85
2021
Q2 		$2.68M Sell
28,645
-19,755
-41% -$1.82M 0.33% 106
2021
Q1 		$4.46M Buy
48,400
+24,005
+98% +$2.03M 0.57% 74
2020
Q4 		$1.78M Sell
24,395
-12,520
-34% -$931K 0.25% 109
2020
Q3 		$2.87M Sell
36,915
-86,290
-70% -$5.94M 0.53% 68
2020
Q2 		$6.85M Sell
123,205
-113,448
-48% -$4.85M 1.4% 18
2020
Q1 		$7.01M Sell
236,653
-27,390
-10% -$927K 2.31% 4
2019
Q4 		$9.56M Buy
264,043
+30,178
+13% +$925K 2.54% 1
2019
Q3 		$6.37M Buy
233,865
+27,395
+13% +$708K 2.08% 11
2019
Q2 		$4.97M Buy
206,470
+52,275
+34% +$1.33M 1.62% 22
2019
Q1 		$4.08M Buy
+154,195
New +$3.65M 1.44% 19

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Lisanti Capital Growth's HZNP Position: Q3 2022 in Review

Lisanti Capital Growth sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 49,397 shares — an estimated $3.94M sold.

Lisanti Capital Growth first reported a position in HZNP in Q1 2019 and held it in 14 quarters. The position peaked at $9.56M in Q4 2019. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Lisanti Capital Growth reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Lisanti Capital Growth sold 49,397 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $3.94M.
  • Lisanti Capital Growth first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 14 quarters.
  • Lisanti Capital Growth's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $9.56M in Q4 2019.
  • 530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Lisanti Capital Growth's 13F filing for Q3 2022, filed 2 Nov 2022.